The treatment here combined pembrolizumab, an immune checkpoint inhibitor, with DNA vaccines. Pembrolizumab blocks PD-1, which is one of the molecular "calm down, do not overreact" signals on T cells. That is useful when your immune system is trying not to torch your healthy tissues, but it is less helpful when a tumor is basically wearing sunglasses indoors and pretending to be invisible.
The vaccines were pTVG-HP and pTVG-AR. pTVG-HP teaches the immune system to recognize prostatic acid phosphatase, or PAP, a prostate-associated antigen. pTVG-AR targets part of the androgen receptor, which is a major driver of prostate cancer biology and, frankly, a repeat offender in this disease. The hope was simple: show T cells more than one mugshot, then let pembrolizumab help them act on it. That logic fits with years of work suggesting prostate cancer is often an immunologically "cold" tumor, meaning T cells either do not show up in force or do not function well once they arrive [2-4].
Two routes, same traffic jam
Sixty patients with metastatic castration-resistant prostate cancer, or mCRPC, were randomized. One arm got pTVG-HP plus pembrolizumab. The other got alternating pTVG-HP and pTVG-AR with pembrolizumab. If the second arm sounds like the "we brought a second keycard in case security locks us out again" strategy, that is basically the vibe.
What happened? The overall signal was encouraging, but not a home run. Median time to progression was 24 weeks in both arms. The 6-month progression-free survival rate was 51% with pTVG-HP alone and 45% with the two-vaccine approach. Median overall survival was 2.8 years overall, with a numerical but not statistically significant difference between arms. A PSA drop of more than 50% happened in 20% of patients in each arm. Among the 20 patients with measurable disease, 6 had a partial response, which is not nothing in mCRPC land, where "not nothing" can be a pretty meaningful category [1].
So the combo clearly did something biologically and clinically. It just did not show that adding the androgen receptor vaccine made the outcomes better in a clear, measurable way.
The awkward part nobody gets to skip
Arm B did broaden T-cell responses, which means the immune system really was reacting to both targets. That is good news if you are thinking mechanistically. Unfortunately, biology then did its usual thing and got weird. The added pTVG-AR vaccine also came with a slight toxicity penalty. Three patients in Arm B developed creatine kinase elevation with or without liver enzyme increases, something not seen in Arm A. That matters because androgen receptor is not unique to tumor tissue. If your target also lives in normal tissues, your immune system may decide to get a little too enthusiastic. Tiny bodyguards are great until they start tackling bystanders.
This is also where the limitations matter. The trial was small, with 60 patients total. Only 20 had measurable disease for formal response assessment. There was no pembrolizumab-only control arm, so we cannot cleanly separate how much of the activity came from vaccination versus checkpoint blockade versus the pairing itself. And while booster immunizations helped a few patients after PSA progression, that subgroup was tiny. Journal club me would absolutely underline all of that three times [1].
Why this still matters
This paper lands in a field where immune checkpoint inhibitors alone have mostly struggled in unselected mCRPC. Large studies like KEYNOTE-921 did not significantly improve outcomes by simply adding pembrolizumab to docetaxel for broad mCRPC populations [5]. That is exactly why this vaccine strategy is interesting. It is trying to solve the upstream problem: maybe the issue is not just that T cells are restrained, but that too few relevant T cells were activated in the first place.
That does not mean this trial changes practice tomorrow morning. It does mean the broader idea still has legs: prime the immune system better, choose antigens carefully, and maybe stop assuming one immunotherapy lever is enough for a tumor this good at evasive driving. If future studies can identify which patients actually mount the right T-cell response, or combine vaccines with smarter biomarker selection, this road may get less clogged [2-4,6].
For now, the take-home is pleasantly modest. The vaccine plus pembrolizumab approach showed real anti-tumor activity. Adding a second vaccine against androgen receptor made the immune response broader, but not clearly better where patients would most want it to count, and it introduced a bit more collateral damage. Cancer biology remains weird, the immune system remains dramatic, and progress sometimes looks less like a victory lap and more like finally finding the correct exit ramp.
References
-
Kyriakopoulos CE, Pachynski RK, Eickhoff JC, Tonelli TP, Jeon D, McNeel DG. Phase 2 trial of pTVG-HP ± pTVG-AR DNA vaccines and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2026. DOI: 10.1136/jitc-2025-014323. PubMed: PMID 42031429
-
Rastogi I, Muralidhar A, McNeel DG. Vaccines as treatments for prostate cancer. Nat Rev Urol. 2023;20(9):544-559. DOI: 10.1038/s41585-023-00739-w. PMCID: PMC9987387
-
Wang J, Zhou K, Zhu H, Wei F, Ma S, Kan Y, Li B, Mao L. Current status and progress of the development of prostate cancer vaccines. J Cancer. 2023;14(5):835-842. DOI: 10.7150/jca.80803. PMCID: PMC10088880
-
Bansal D, Reimers MA, Knoche EM, Pachynski RK. Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. Cancers (Basel). 2021;13(2):334. DOI: 10.3390/cancers13020334. PMCID: PMC7831137
-
Petrylak DP, Ratta R, Matsubara N, et al. Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial. J Clin Oncol. 2025;43(14):1638-1649. DOI: 10.1200/JCO-24-01283. PubMed: PMID 40043230
-
Dwyer L, Leslie C, Mellor R, Scheinberg T, Taylor RA, Horvath LG. Immunotherapy in metastatic prostate cancer. Ther Adv Med Oncol. 2025. DOI: 10.1177/17588359251347857
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.